These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 39308826)

  • 1. Clinical outcomes in lupus nephritis patients treated with belimumab in real-life setting: a retrospective comparative study in China.
    Lin Z; Jiang B; Wang W; Chen C; Wang Y; Wan J; Xu Y
    PeerJ; 2024; 12():e18028. PubMed ID: 39308826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study.
    Su Z; Zhang C; Gao C; Li C; Li R; Zheng Z
    Arthritis Res Ther; 2024 Sep; 26(1):163. PubMed ID: 39294688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis.
    Li H; Chen C; Yang H; Tu J
    Eur J Pediatr; 2024 Sep; 183(9):3987-3995. PubMed ID: 38940925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
    Gatto M; Saccon F; Andreoli L; Bartoloni E; Benvenuti F; Bortoluzzi A; Bozzolo E; Brunetta E; Canti V; Cardinaletti P; Ceccarelli F; Ciccia F; Conti F; De Marchi G; de Paulis A; De Vita S; Emmi G; Faggioli P; Fasano S; Fredi M; Gabrielli A; Gasparotto M; Gerli R; Gerosa M; Govoni M; Gremese E; Laria A; Larosa M; Mosca M; Orsolini G; Pazzola G; Petricca L; Ramirez GA; Regola F; Rossi FW; Rossini M; Salvarani C; Scarpato S; Tani C; Tincani A; Ubiali T; Urban ML; Zen M; Doria A; Iaccarino L
    J Autoimmun; 2021 Nov; 124():102729. PubMed ID: 34600347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrapolation of the Efficacy and Pharmacokinetics of Belimumab to Support its Use in Children with Lupus Nephritis.
    Dimelow R; Liefaard L; Green Y; Tomlinson R
    Clin Pharmacokinet; 2024 Sep; 63(9):1313-1326. PubMed ID: 39320441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis.
    Zhao L; Wang W; Wu L; Wu T; Tu J; Wu X; Sun F; Ding H; Shen N; Wu H; Zhu J; Sun L; Ye S
    Lupus Sci Med; 2024 May; 11(1):. PubMed ID: 38806217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
    Furie R; Rovin BH; Houssiau F; Contreras G; Teng YKO; Curtis P; Green Y; Okily M; Madan A; Roth DA
    Clin J Am Soc Nephrol; 2022 Nov; 17(11):1620-1630. PubMed ID: 36302567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belimumab in early systemic lupus erythematosus: A propensity score matching analysis.
    Lu C; He N; Dou L; Yu H; Li M; Leng X; Zeng X
    Immun Inflamm Dis; 2024 Aug; 12(8):e1362. PubMed ID: 39172013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study.
    Zhang S; Qiu Q; Zeng S; Li H; Xu L; Jie L; Hu X; Xiao Y; Chen D; Zhan Z; Liang L; Yu Q; Xu H
    Clin Rheumatol; 2024 Jan; 43(1):199-208. PubMed ID: 37982925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Belimumab in Lupus Nephritis Patients: A Real-World Observational Study in China.
    Tan M; Xu J; Tan Y; Qu Z; Yu F; Zhao M
    Kidney Dis (Basel); 2023 May; 9(3):218-228. PubMed ID: 37497208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness of belimumab in patients with lupus in China: RELIABLE observational cohort study protocol.
    Fan L; Tang Z; He X; He X; Zhang Z; Juliao P
    Lupus Sci Med; 2024 Jul; 11(2):. PubMed ID: 38991834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
    Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy.
    Liu D; Zhou Q; Wang D; Qu Y; Guo Q; Wen J; Yu Q; Ai J
    Lupus; 2022 Oct; 31(12):1456-1467. PubMed ID: 35960182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.
    Zhang H; Chen J; Zhang Y; Zhao N; Xu D
    Ren Fail; 2023 Dec; 45(1):2207671. PubMed ID: 37194710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases.
    de la Rubia Navarro M; Ivorra Cortés JR; Grau García E; Román Ivorra JA
    Med Clin (Barc); 2022 Oct; 159(7):344-346. PubMed ID: 35811138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.
    Fan C; Yang T; Zheng S; Liao X; Xie R; Chen S; Li J
    Front Immunol; 2024; 15():1423035. PubMed ID: 38947321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of belimumab therapy for patients with lupus nephritis: A meta-analysis and a propensity score-matched case-control study.
    Zhang K; Qi T; Guo D; Liu Y
    Immun Inflamm Dis; 2023 Jul; 11(7):e954. PubMed ID: 37506137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman.
    Fließer EE; Korsten P; Koziolek MJ; Niewold TB; Patschan D; Müller GA; Patschan SA
    Lupus; 2013 Dec; 22(14):1523-5. PubMed ID: 24014569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient).
    Binda V; Trezzi B; Del Papa N; Beretta L; Frontini G; Porata G; Fabbrini P; Pozzi MR; Messa P; Sinico RA; Moroni G
    J Nephrol; 2020 Oct; 33(5):1019-1025. PubMed ID: 32002799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective.
    Liu T; Neuner R; Thompson A; Pottackal G; Petullo D; Liu J; Nikolov N; Sahajwalla C; Doddapaneni S; Chen J
    Lupus; 2022 Apr; 31(4):424-432. PubMed ID: 35238725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.